Insight Molecular Diagnostics Inc. 8-K/A

What Happened
Insight Molecular Diagnostics, Inc. (iMDx) announced on February 20, 2026 that it entered into a Specimen Collection Agreement with Quest Diagnostics for specimen collection‑related services tied to the Company’s GraftAssureCore™ test. The GraftAssureCore test is a blood test designed to measure donor‑derived cell free DNA (dd‑cfDNA) using a novel PCR‑based measurement platform. The company filed the disclosure on Form 8‑K dated May 13, 2026; the filing reports the arrangement under Item 8.01 (Other Events) though it relates to a material definitive agreement.

Key Details

• Agreement partner: Quest Diagnostics (national clinical laboratory and specimen collection network).
• Announcement date: February 20, 2026; Form 8‑K filed May 13, 2026.
• Subject: specimen collection‑related services for GraftAssureCore (dd‑cfDNA PCR‑based blood test).
• Financial terms or specific commercial/volume commitments were not disclosed in the 8‑K.

Why It Matters
A specimen collection agreement with a large provider like Quest Diagnostics can help iMDx streamline patient sample collection and broaden access to its GraftAssureCore test, which may be important for future test utilization and commercial rollout. The filing does not disclose financial terms or any immediate revenue impact, so investors should view this as an operational partnership announcement rather than a near‑term revenue disclosure.